Orion Pharma Limited announcements
187 Dhaka Stock Exchange announcements for Orion Pharma Limited (ORIONPHARM) since 2013: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2023 (22).
- Credit Rating Agency of Bangladesh Limited (CRAB) has announced the Surveillance Rating of the Company as \"AA3\" in the
Credit Rating Agency of Bangladesh Limited (CRAB) has announced the Surveillance Rating of the Company as \"AA3\" in the long term and \"ST-3\" in the short term along with stable outlook based on audited financial statements up to June 30, 2023, and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Trading of the shares of the company will resume on 04.12.2023.
Trading of the shares of the company will resume on 04.12.2023.
- Trading of the shares of the company will remain suspended on record date i.e., 03.12.2023.
Trading of the shares of the company will remain suspended on record date i.e., 03.12.2023.
- Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 29.11.2023 to 30.11.2023 and trading of the shares will remain suspended on record date i.e., 03.12.2023 for AGM and EGM.
- The auditor of the company has given the \"Emphasis of Matter\" paragraph in the Auditor\'s Report of the company for th
The auditor of the company has given the \"Emphasis of Matter\" paragraph in the Auditor\'s Report of the company for the year ended June 30, 2023. To view the details, please visit: https://www.dsebd.org/assets/pdf/2.ORIONPHARM.pdf
- Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 0.76 for July-September 2023 as against Tk. 0.72 for July-September 2022; Consolidated NOCFPS was Tk. 3.89 for July-September 2023 as against Tk. 2.25 for July-September 2022. Consolidated NAV per share (including revaluation surplus) was Tk. 89.65 as on September 30, 2023 and Tk. 88.99 as on June 30, 2023. Consolidated NAV per share (excluding revaluation surplus) was Tk. 81.82 as on September 30, 2023 and Tk. 81.15 as on June 30, 2023.
- The Board of Directors has recommended 10\% Cash Dividend for the year ended June 30, 2023. The Board has also considere
The Board of Directors has recommended 10\% Cash Dividend for the year ended June 30, 2023. The Board has also considered and recommended the proposal for approval of the shareholders regarding Related Party Transaction for the Financial year ended June 30, 2023 and in this regard, the Board also advised to hold an EGM. Date of AGM and EGM: 26.12.2023, Time of AGM and EGM: 3:00 PM and 3:45 PM respectively, Venue: Digital Platform. Record Date for AGM and EGM: 03.12.2023. (cont.1)
- (Continuation news of ORIONPHARM): The Company has reported Consolidated EPS of Tk. 2.74, Consolidated NAV per share (In
(Continuation news of ORIONPHARM): The Company has reported Consolidated EPS of Tk. 2.74, Consolidated NAV per share (Including Revaluation Surplus) of Tk. 88.99, Consolidated NAV per share (Excluding Revaluation Surplus) of Tk. 81.15 and Consolidated NOCFPS of Tk. 10.65 for the year ended June 30, 2023 as against Tk. 3.62, Tk. 82.53, Tk. 74.62 and Tk. 4.96 respectively for the year ended June 30, 2022. (cont.2)
The first part of this announcement is missing from the archive. - Price Limit Open
There will be no price limit on the trading of the shares of the Company on today (13.11.2023) following its corporate declaration. However, the floor price shall be applicable accordingly.
- Dividend Declaration and EGM for Related Party Transaction
(Continuation news of ORIONPHARM): Reasons for significant changes in NOCFPS: NOCFPS has been increased due to increase in cash collection from customers and others. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2023 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2023.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 12, 2023 at 4:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
- (Q3 Un-audited): Consolidated EPS was Tk. 0.53 for January-March 2023 as against Tk. 1.05 for January-March 2022; Consol
(Q3 Un-audited): Consolidated EPS was Tk. 0.53 for January-March 2023 as against Tk. 1.05 for January-March 2022; Consolidated EPS was Tk. 2.44 for July 2022-March 2023 as against Tk. 3.07 for July 2021-March 2022. Consolidated NOCFPS was Tk. 6.85 for July 2022-March 2023 as against Tk. 3.44 for July 2021-March 2022. Consolidated NAV per share (excluding Revaluation Surplus) was Tk. 79.51 as on March 31, 2023 and Tk. 74.62 as on June 30, 2022. (cont.1)
- (Continuation news of ORIONPHARM): NAV per share (including Revaluation Surplus) was Tk. 87.37 as on March 31, 2023 and
(Continuation news of ORIONPHARM): NAV per share (including Revaluation Surplus) was Tk. 87.37 as on March 31, 2023 and Tk. 82.53 as on June 31, 2022. Reason for deviation in EPS and NOCFPS: EPS has been decreased due to increases of goods sold and cost of power generation. (cont.2)
The first part of this announcement is missing from the archive. - Q3 Financials
(Continuation news of ORIONPHARM): NOCFPS has been increased due to increase in cash collection from customer and power plants has been generating revenues. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 30, 2023 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2023.
- Dividend Disbursement
The Company has informed that it has disbursed the cash dividend for the year ended June 30, 2022 to the respective shareholders.
- (Q2 Un-audited): Consolidated EPS was Tk. 1.19 for October-December 2022 as against Tk. 1.72 for October-December 2021;
(Q2 Un-audited): Consolidated EPS was Tk. 1.19 for October-December 2022 as against Tk. 1.72 for October-December 2021; Consolidated EPS was Tk. 1.91 for July-December 2022 as against Tk. 2.02 for July-December 2021. Consolidated NOCFPS was Tk. 5.62 for July-December 2022 as against Tk. 1.87 for July-December 2021. Consolidated NAV per share including revaluation surplus was Tk. 91.75 as on December 31, 2022 and Tk. 82.53 as on June 30, 2022. Consolidated NAV per share excluding (cont.1)
- (Continuation news of ORIONPHARM): revaluation surplus was Tk. 83.87 as on December 31, 2022 and Tk. 74.62 as on June 30
(Continuation news of ORIONPHARM): revaluation surplus was Tk. 83.87 as on December 31, 2022 and Tk. 74.62 as on June 30, 2022. NOCFPS has increased significantly mainly due to increase in cash collection from customer. In corresponding period, the power plants were not in operation and accordingly there was no revenue generation as well as cash collection from these power plants. (cont.2)
The first part of this announcement is missing from the archive. - Q2 Financials
(Continuation news of ORIONPHARM): However, the power plants have started generating revenue and cash collection has increased which has resulted in increase of NOCFPS in this reporting period. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2022.
- Credit Rating Agency of Bangladesh Limited (CRAB) has assigned the Entity rating (Surveillance) of the Company as \"AA3\
Credit Rating Agency of Bangladesh Limited (CRAB) has assigned the Entity rating (Surveillance) of the Company as \"AA3\" in the long term and \"ST-3\" in the short term along with stable outlook based on audited financial statements as of June 30, 2022, bank liability position as of September 30, 2022 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.